Citi Pharma (KAR:CPHL) Net Margin %: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨75.08
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Net Margin %?

Citi Pharma KAR:CPHL +0.37% 15 Net Margin % is 0.00% as of . 20. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 962 Drug Manufacturers companies, Citi Pharma ranks worse than 103950% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Citi Pharma's Net Income for the six months ended in . 20 was ₨0.00 Mil. Citi Pharma's Revenue for the six months ended in . 20 was ₨0.00 Mil. Therefore, Citi Pharma's net margin for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Citi Pharma's Net Margin % or its related term are showing as below:


KAR:CPHL's Net Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.56
* Ranked among companies with meaningful Net Margin % only.

Citi Pharma  (KAR:CPHL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Citi Pharma Net Margin % Related Terms

Citi Pharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Citi Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Net Margin % Chart

Citi Pharma Annual Data
Trend
Net Margin %

Citi Pharma Semi-Annual Data
Net Margin %

KAR:CPHL vs ZTS, UTHR, VTRS: Net Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citi Pharma Net Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Citi Pharma's Net Margin % falls into.


KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Citi Pharma's Net Margin for the fiscal year that ended in . 20 is calculated as

Net Margin=Net Income (A: . 20 )/Revenue (A: . 20 )
=/
= %

Citi Pharma's Net Margin for the quarter that ended in . 20 is calculated as

Net Margin=Net Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Citi Pharma (KAR:CPHL) has a Net Margin % of 0.00% as of . 20. Net margin is the ratio of total net income to net sales. View historical data on Citi Pharma and its competitors. According to the industry distribution chart, Citi Pharma ranks #999999 out of 962 companies in the Drug Manufacturers industry.
Is Citi Pharma's Net Margin % too high?
Citi Pharma's current Net Margin % is 0.00%. Based on the distribution chart, Citi Pharma ranks #999999 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Citi Pharma ranks #999999 out of 962 companies for Net Margin %. This places Citi Pharma in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Citi Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citi Pharma's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current Net Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨75.08
Price